Financials data is unavailable for this security.
View more
Year on year Fusen Pharmaceutical Co Ltd had net income fall 4.83% from a loss of 34.61m to a larger loss of 36.28m despite a 15.02% increase in revenues from 491.76m to 565.61m.
| Gross margin | 53.18% |
|---|---|
| Net profit margin | -21.08% |
| Operating margin | -17.78% |
| Return on assets | -6.77% |
|---|---|
| Return on equity | -15.70% |
| Return on investment | -13.96% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Fusen Pharmaceutical Co Ltd fell by 93.26m. Cash Flow from Financing totalled 88.50m or 15.65% of revenues. In addition the company used 73.33m for operations while cash used for investing totalled 108.32m.
| Cash flow per share | -0.0517 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.7654 |
|---|---|
| Tangible book value per share | 0.7237 |
More ▼
Balance sheet in CNYView more
| Current ratio | 0.7299 |
|---|---|
| Quick ratio | 0.526 |
| Total debt/total equity | 0.6737 |
|---|---|
| Total debt/total capital | 0.4031 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items dropped -5.40%.
| Div yield(5 year avg) | 0.25% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -712.57 |
More ▼
